Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

Supernus and Sunovion are the current leaders in terms of likelihood of getting a non-stimulant to market. Supernus has two potential shots on goal with one of them being a novel indication.

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care ...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Supernus Pharmaceuticals Inc., a Rockville-based pharmaceutical company focused on products for the treatment of central nervous system diseases, reported ...

Supernus Pharmaceuticals made a bold acquisition after the bell on Tuesday that had the stock rally 20% on Wednesday. Further capital appreciation may lay ahead as investors factor in the positive ...

Supernus Pharmaceuticals (NASDAQ: SUPN), currently valued at $2.03 billion, has agreed to acquire Sage Therapeutics for $8.50 per share in cash, representing a total price of approximately $561 ...

Supernus Pharmaceuticals beat analysts’ revenue expectations by 12.2% last quarter, reporting revenues of $174.2 million, up 6% year on year. It was a very strong quarter for the company, ...

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are ...

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) increased during the last reporting period, rising from 4.18M to 4.23M. This put 11.46% of the company's publicly available shares ...

Supernus Pharmaceuticals Inc., of Rockville, plans to buy privately-held Biscayne Neurotherapeutics, of Miami, Florida, the company announced Thursday.